TGF‐β1 is involved in tumour growth. Four TGFB1 SNPs and TGF‐β1 production by stimulated PBMC were determined in seventy‐eight gastric adenocarcinoma patients. In addition, TGF‐β1 levels were measured in the plasma of further thirty patients. rs1800471‐G/C genotype was prevalent in patients (20.7%) compared to controls (8.4%), as it also was the rs1800468 SNP‐G/A genotype in stage IV patients (20.7%) compared to stage I, II and III patients, combined (10.3%). Conversely, the T/T rs1800469 SNP‐T/T genotype was absent in the former group and present in 19.0% in the latter. Furthermore, the rs1800469‐C/rs1800470‐T (CT) haplotype was found in 15.0% of stage IV patients as compared to 3.0% of the remaining patients (3.0%) and also identifies patients with worse five‐year life expectancy (P = .03). TGF‐β1 synthesis by stimulated PBMCs was significantly lower in patients with the risk SNPs or haplotype, compared to the alternative genotype. Finally, TGF‐β1 plasma levels were lower in patients with worse life expectancy. Analysis of TGFB1 SNPs and measurement of plasma TGF‐β1 levels serves to identify patients at risk of developing a more aggressive disease.

中文翻译：

---

TGFB1 多态性和 TGF-β1 血浆水平可识别具有较低存活率和播散性疾病的胃腺癌患者

TGF-β1参与肿瘤生长。在 78 名胃腺癌患者中测定了 4 个 TGFB1 SNP 和受刺激的 PBMC 产生的 TGF-β1。此外，还测量了另外 30 名患者血浆中的 TGF-β1 水平。rs1800471-G/C 基因型在患者中普遍存在（20.7%）与对照组（8.4%）相比，因为它也是 rs1800468 SNP-G/A 基因型在 IV 期患者（20.7%）中与 I、II 和 III 期相比患者，加起来（10.3%）。相反，T/T rs1800469 SNP-T/T 基因型在前组中不存在，而在后者中以 19.0% 的比例存在。此外，在 15.0% 的 IV 期患者中发现 rs1800469-C/rs1800470-T (CT) 单倍型，而在其余患者中为 3.0% (3.0%)，并且还确定了五年预期寿命较差的患者 ( P = .03)。与替代基因型相比，具有风险 SNP 或单倍型的患者通过刺激的 PBMC 合成 TGF-β1 显着降低。最后，预期寿命较差的患者血浆 TGF-β1 水平较低。分析 TGFB1 SNP 和测量血浆 TGF-β1 水平有助于识别有发展为更具侵袭性疾病风险的患者。